SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Good evidence begets good policy: or so it should be
10 references·0 citing·43 second hop
Good evidence begets good policy: or so it should be (2012)Good evidence begets good policy: or so i…Cost‐effectiveness of additional blood screening tests in the Netherlands (2011)Cost‐effectiveness of additio…Health economics of blood transfusion safety – focus on sub-Saharan Africa (2009)Health economics of blood tra…Expensive blood safety initiatives may offer less benefit than we think (2009)Expensive blood safety initia…Cost‐effectiveness of additional hepatitis B virus nucleic acid testing of individual donations or minipools of six donations in the Netherlands (2008)Cost‐effectiveness of additio…Cost-Effectiveness Analysis: What It Really Means for Transfusion Medicine Decision Making (2008)Cost-Effectiveness Analysis: …Economic analyses of blood safety and transfusion medicine interventions: a systematic review (2004)Economic analyses of blood sa…Cost‐effectiveness of nucleic acid test screening of volunteer blood donations for hepatitis B, hepatitis C and human immunodeficiency virus in the United States (2004)Cost‐effectiveness of nucleic…The cost‐effectiveness of NAT for HIV, HCV, and HBV in whole‐blood donations (2003)The cost‐effectiveness of NAT…Cost‐effectiveness of expanded human immunodeficiency virus‐testing protocols for donated blood (1997)Cost‐effectiveness of expande…Declining value of alanine aminotransferase in screening of blood donors to prevent posttransfusion hepatitis B and C virus infection. The Retrovirus Epidemiology Donor Study (1995)Declining value of alanine am…The NICE Cost-Effectiveness Threshold (2008)Emerging infectious disease agents and their potential threat to transfusion safety (2009)Blood donor selection in European Union directives: room for improvement. (2016)Reconsideration of blood donation testing strategy for human T‐cell lymphotropic virus in Australia (2017)Assessing the value of screening tools: reviewing the challenges and opportunities of cost-effectiveness analysis (2018)Foundations of Cost-Effectiveness Analysis for Health and Medical Practices (1977)The Role of Cost-effectiveness Analysis in Health and Medicine (1996)The role of cost-effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and Medicine (1996)The cost of blood: did you pay too much or did you get a good deal? (2010)Five‐Hundred Life‐Saving Interventions and Their Cost‐Effectiveness (1995)Health-State Utilities and Quality of Life in Hepatitis C Patients (2003)Transfusion sanguine : en toute sécurité d’approvisionnement (2015)Cost effectiveness of adding nucleic acid testing to hepatitis B , hepatitis C , and human immunodeficiency virus screening of blood donations in Z imbabwe (2016)Cost-benefit analysis of serological and nucleic acid testing for hepatitis B virus in blood donors in southern China (2024)Clinical Decision Analysis (1980)Donor Transaminase and Recipient Hepatitis (1981)EVALUATING THE COST-EFFECTIVENESS OF CLINICAL AND PUBLIC HEALTH MEASURES (1998)Handling uncertainty when performing economic evaluation of healthcare interventions. (1999)Preference-Based Measures in Economic Evaluation in Health Care (2000)Clinical decision analysis (2005)World Development Report 1990. (1990)Recommendations of the Panel on Cost-Effectiveness in Health and Medicine (1996)Optimal selection of screening assays for infectious agents in donated blood (2011)Transmission of HIV Through Blood – How To Bridge the Knowledge Gap (2011)Robust Postdonation Blood Screening Under Prevalence Rate Uncertainty (2017)A population‐based binational register for monitoring long‐term outcome and possible disease concordance among blood donors and recipients (2006)Recommendations for Reporting Cost-effectiveness Analyses (1996)The Risk of Transfusion-Transmitted Viral Infections (1996)Current prevalence and incidence of infectious disease markers and estimated window‐period risk in the American Red Cross blood donor population (2002)Probability of Viremia with HBV, HCV, HIV, and HTLV among Tissue Donors in the United States (2004)Estimating the cost of blood: past, present, and future directions (2007)Transfusion‐associated infections: 50 years of relentless challenges and remarkable progress (2010)The Markov Process in Medical Prognosis (1983)Equity and the economic evaluation of healthcare (2001)A review and critique of modelling in prioritising and designing screening programmes (2007)Methods for the economic evaluation of health care programmes (1987)Perception of Risk (1987)Cost-Effectiveness in Health and Medicine (1996)Residual risk of transfusion transmitted human immunodeficiency virus, hepatitis B virus, hepatitis C virus and human T lymphotrophic virus (2005)Lessons from Cost-Effectiveness Research for United States Public Health Policy (2007)Department of Labor (1941)BLOOD DONORS AND BLOOD COLLECTION: Web interface–supported transmission risk assessment and cost‐effectiveness analysis of postdonation screening: a global model applied to Ghana, Thailand, and the Netherlands (2009)The Politics of Blood (2012)
this work references cited by second hop

References

  • 2003The cost‐effectiveness of NAT for HIV, HCV, and HBV in whole‐blood donations264 cited
  • 2004Cost‐effectiveness of nucleic acid test screening of volunteer blood donations for hepatitis B, hepatitis C and human immunodeficiency virus in the United States136 cited
  • 1997Cost‐effectiveness of expanded human immunodeficiency virus‐testing protocols for donated blood130 cited
  • 1995Declining value of alanine aminotransferase in screening of blood donors to prevent posttransfusion hepatitis B and C virus infection. The Retrovirus Epidemiology Donor Study124 cited
  • 2008Cost-Effectiveness Analysis: What It Really Means for Transfusion Medicine Decision Making72 cited
  • 2011Cost‐effectiveness of additional blood screening tests in the Netherlands35 cited
  • 2004Economic analyses of blood safety and transfusion medicine interventions: a systematic review35 cited
  • 2009Health economics of blood transfusion safety – focus on sub-Saharan Africa28 cited
  • 2008Cost‐effectiveness of additional hepatitis B virus nucleic acid testing of individual donations or minipools of six donations in the Netherlands22 cited
  • 2009Expensive blood safety initiatives may offer less benefit than we think11 cited

Cited by

No citing works inside the corpus for this window.

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work